RT Journal Article
SR Electronic
T1 Relapse and non-relapse prediction using a sensitive circulating tumor DNA assay during colorectal cancer postoperative surveillance
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.09.03.22279571
DO 10.1101/2022.09.03.22279571
A1 Sasaki, Tomoko
A1 Iwaya, Takeshi
A1 Yaegashi, Mizunori
A1 Idogawa, Masashi
A1 Hiraki, Hayato
A1 Abe, Masakazu
A1 Koizumi, Yuka
A1 Sasaki, Noriyuki
A1 Yashima-Abo, Akiko
A1 Fujisawa, Ryosuke
A1 Endo, Fumitaka
A1 Tange, Shoichiro
A1 Hirano, Tomomi
A1 Otsuka, Koki
A1 Sasaki, Akira
A1 Masuda, Mari
A1 Fujita, Masashi
A1 Nakagawa, Hidewaki
A1 Takahashi, Fumiaki
A1 Sasaki, Yasushi
A1 Tokino, Takashi
A1 Nishizuka, Satoshi S.
YR 2022
UL http://medrxiv.org/content/early/2022/09/06/2022.09.03.22279571.abstract
AB This study investigated whether a circulating tumor DNA (ctDNA) assay using digital PCR (dPCR) could provide early relapse detection and disease-free corroboration at molecular level during postoperative surveillance of colorectal cancer (CRC).METHODS The ctDNA dynamics of 52 patients with CRC measured by dPCR targeting 87 individual tumor-specific mutations (1-5 per patient) were compared with results for conventional surveillance using serum tumor markers and computed tomography scanning (CTS). The data were collected between March 2016 and June 2018.RESULTS A total of 1,526 prospectively collected plasma samples from 867 timepoints were analyzed. The average number of ctDNA assays per patient was 16.4 and the median follow-up was 1,503 days (range 322-1,951 days). Among patients with Stage II or higher disease who underwent curative resection as their initial surgery (n=47), patients who were ctDNA-positive during the postoperative period (n= 9) showed a higher risk of relapse than those who had sustained ctDNA-negative results (n=38) (hazard ratio 56.3, 95%CI 7.8–407.0, P < 0.0001). Elevated ctDNA levels were observed in nine of 10 clinical-relapse patients (11 of 13 events) with an average lead time from a ctDNA-positive time-point to clinical relapse of 191.9 days (range 0-376 days). Given periodic CTS surveillance with ctDNA, 218 (57.1%) CTSs were presumed to be unnecessary for clinical relapse detection and a ctDNA assay would still provide a lead time of 307 days (range 45–582 days).CONCLUSION Our findings suggest that the ctDNA assay can reduce the frequency of CTS for relapse diagnosis during postoperative surveillance of CRC. UMIN Clinical Trial Registry number, UMIN000045114Competing Interest StatementThe authors have declared no competing interest.Clinical TrialUMIN Clinical Trial Registry number, UMIN000045114Funding StatementThis work was supported by a Grant-in-Aid for Scientific Research KAKENHI [16K19951, 16K19952, 16H06279, 17K10605, 19K09224, 20K09064, 20K08966, and 21K07223], Keiryokai Collaborative Research Grant [#136 and #145], and Iwate Prefectural Research Grants [H30, R2, and R3]Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Institutional Review Board of Iwate Medical University (IRB #HGH28-15 and #MH2021-073).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.